Sign up to save your podcasts
Or
Share A Look Behind the Curtain: Exploring Lower-Risk MDS-RS & MDS/MPN-RS-T
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A Look Behind the Curtain: Exploring Lower-Risk MDS-RS & MDS/MPN-RS-T
CME credits: 0.25
Valid until: 08-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/a-look-behind-the-curtain-exploring-lower-risk-mds-rs-mdsmpn-rs-t/13992/
Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 08-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/a-look-behind-the-curtain-exploring-lower-risk-mds-rs-mdsmpn-rs-t/13992/
Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.
=